RNA-seq was performed on liver samples from all treatment groups to further investigate the role of Cyp2b in the development and progression of NASH because of the observed changes in serum markers of liver injury in the CDAHFD-treated groups, especially within the relatively resistant Cyp2b-null female mice. Here, CYP2B6 is linked to metabolic dysfunction-associated steatohepatitis.